The main goal for CML patients is to achieve a durable remission, known as treatment-free remission, which first requires maintaining a deep molecular response (DMR) (BCR::ABL1 ≤ 0.01% or undetectable; limit of detection of 0.001%) [23]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.